Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins
https://doi.org/10.20538/1682-0363-2022-3-132-139
Abstract
HER2-positive breast cancer occurs in 15–20% of breast cancer patients and is associated primarily with a poor prognosis of the disease and the need for highly specific targeted therapy. Despite the clinical importance of determining HER2/neu, traditional diagnostic methods have their disadvantages and require the study of new additional research techniques.
The information presented in this review makes it possible to consider current trends in the radionuclide diagnosis of HER2-positive breast cancer using the latest class of alternative scaffold proteins and to consider various aspects of their use in clinical practice.
Supporting agencies: The study was carried out within the grant of the Ministry of Science and Higher Education (agreement No. 075-15-2022-1103) on the topic “Development of targeted molecules on the basis of scaffold proteins for diagnosis and therapy of cancers: theranostic approach”
About the Authors
O. D. Bragina
Cancer Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of Sciences; National Research Tomsk Polytechnic University
Russian Federation
Competing Interests:
Russian Federation
5, Kooperativny Str., 634009, Tomsk; 30, Lenina Av., 634050, Tomsk
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article
V. I. Chernov
Cancer Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of Sciences; National Research Tomsk Polytechnic University
Russian Federation
Competing Interests:
Russian Federation
5, Kooperativny Str., 634009, Tomsk; 30, Lenina Av., 634050, Tomsk
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article
S. M. Deyev
National Research Tomsk Polytechnic University; Shemyakin – Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
30, Lenina Av., 634050, Tomsk; 16/10, Miklukho-Maklaya Str., 117997, Moscow
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article
V. M. Tolmachev
National Research Tomsk Polytechnic University; Uppsala University
Russian Federation
Competing Interests:
Russian Federation
30, Lenina Av., 634050, Tomsk; 7, Dag Hammarskjölds väg, Segerstedthuset, 7523600000000000000000000000000, Uppsala
Competing Interests:
The authors declare the absence of obvious or potential conflicts of interest related to the publication of this article
References
1. Han L., Li L., Wang N., Xiong Y., Li Y., Gu Y. Relationship of epidermal growth factor receptor expression with clinical symptoms and metastasis of invasive breast cancer. Interferon Cytokine Res. 2018;38(12):578–582. DOI: 10.1089/jir.2018.0085.
2. Zavyalova M., Vtorushin S., Krakhmal N., Savelieva O., Tashireva L., Kaigorodova E. et al. Clinicopathological features of non-specific invasive breast cancer according to its molecular subtypes. Experimental Oncology. 2016;38(2):122–127.
3. Pernas S., Tolaney S.M. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther. Adv. Med. Oncol. 2019;11:1758835919833519. DOI: 10.1177/1758835919833519.
4. Babyshkina N., Malinovskaya E., Cherdyntseva N., Patalyak S., Bragina O., Tarabanovskaya N. et al. Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population. Medical Oncology. 2014;31(9):1–12. DOI: 10.1007/s12032-014-0165-7.
5. Wolff A.C., Hammond M.E.H., Allison K.H., Harvey B.E., Mangu P.B., Bartlett J.M. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/ College of American pathologist clinical practice guideline focused update. Pathol. Lab. Med. 2018;142(11):1364–1382. DOI: 10.5858/arpa.2018-0902-SA.
6. Tsai Y.F., Tseng L.M., Lien P.J., Hsu C., Lin Y., King K. et al. HER2 immunohistochemically scores provide prognos tic information for patients with HER2-type invasive breast cancer. Histopathology. 2019;74(4):578–586. DOI: 10.1111/his.13801.
7. Ahn S., Woo J., Lee K., Park S.Y. Her2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J. Pathol. Transl. Med. 2020;54(1):34–44. DOI: 10.4132/jptm.2019.11.03.
8. Agersborg S., Mixon C., Nguyen T., Aithal S., Sudarsanam S., Blocker F. et al. Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplifica tion. Breast Cancer Res. Treat. 2018;170(2):321–328. DOI: 10.1007/s10549-018-4755-5.
9. Lower E.E., Khan S., Kennedy D., Baughman R.P. Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site. Breast Cancer – Targets and Therapy. 2017;9:515–520. DOI: 10.2147/BCTT.S137709.
10. Griguolo G., Pascual T., Dieci M.V., Guarneri V., Prat A. Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. J. Immunother. Cancer. 2019;7(1):90. DOI: 10.1186/s40425-0190548-6.
11. Tolmachev V. Orlova A., Sorensen J. The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer. Semin. Cancer Biol. 2021;72:185–197. DOI: 10.1016/j.semcancer.2020.10.005
12. Garousi J., Orlova A., Freid F.Y., Tolmachev V. Imaging using radiolabelled targeted proteins: radioimmunodetec tion and beyond. EJNMMI Radiopharmacy and Chemistry. 2020;5(1):16. DOI: 10.1186/s41181-020-00094-w.
13. Брагина О.Д., Чернов В.И., Зельчан Р.В., Синилкин И.Г., Медведева А.А., Ларкина М.С. Альтернативные каркасные белки в радионуклидной диагностике злокачественных образований. Бюллетень сибирской медицины. 2019;18(3):125–133. DOI: 10.20538/1682-0363-2019-3-125133.
14. Krasniqi A., D’Huyvetter M., Devoogdt N., Frejd F.Y., Sorensen J., Orlova A. et al. Same-day imaging using small proteins: clinical experience and translational prospects in oncology. J. Nucl. Med. 2018;59(6):885–891. DOI: 10.2967/jnumed.117.199901.
15. Tolmachev V., Gronroos T.J., Yim C.B., Garosi J., Yue Y., Grimm S. et al. Molecular design of radiocopper-labelled Affibody molecules. Sci. Rep. 2018;8(1):6542. DOI: 10.1038/s41598-018-24785-2.
16. Sorensen J., Sandberg D., Sandstrom M., Wennborg A., Feldwisch J., Tolmachev V. et al. First-in-human molecu lar imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. J. Nucl. Med. 2014;55(5):730–735. DOI: 10.2967/jnumed.113.131243.
17. Sandström M., Lindskog K., Velikyan I., Wennborg A., Feldwisch J., Sandberg D. et al. Biodistribution and radiation dosimetry of the anti-HER2 Affibody molecule 68Ga-ABY-025 in breast cancer patients. J. Nucl. Med. 2016;57(6):867–871. DOI: 10.2967/jnumed.115.169342.
18. Sörensen J., Velikyan I., Sandberg D., Wennborg A., Feldwisch J., Tolmachev V. et al. Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 affibody PET/CT. Theranostics. 2016;6(2):262–271. DOI: 10.7150/thno.13502.
19. Sandberg D., Tolmachev V., Velikyan I., Olofsson H., Wennborg A., Feldwisch J. et al. Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT. Eur. J. Nucl. Med. Mol. Imaging. 2017;44(8):1337– 1346. DOI: 10.1007/s00259-017-3650-3.
20. Garousi J., Lindbo S., Borin J., von Witting E., Vorobyeva A., Oroujeni M. et al. Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours. Eur. J. Pharm. Biopharm. 2019;134:37–48. DOI: 10.1016/j.ejpb.2018.11.004.
21. Von Witting E., Garousi J., Lindbo S., Vorobyeva A., Altai M., Oroujeni M. et al. Selection of the optimal macrocyclic chelators for labeling with 111 In and 68 Ga improves contrast ofHER2 imaging using engineered scaffold protein ADAPT6. Eur. J. Pharm. Biopharm. 2019;140:109–120. DOI: 10.1016/j.ejpb.2019.05.008.
22. Bragina O., Witting E., Garousi J., Zelchan R., Sandström M., Medvedeva A. et al. Phase I study of 99mTc-ADAPT6, a scaffold protein-based probe for visualization of HER2 expression in breast cancer. J. Nucl. Med. 2021;62(4):493–499. DOI: 10.2967/jnumed.120.248799.
23. Брагина О.Д., Чернов В.И., Гарбуков Е.Ю., Дорошенко А.В., Воробьева А.Г., Орлова А.М. и др. Возможности радионуклидной диагностики Her2-позитивного рака молочной железы с использованием меченных технецием-99m таргетных молекул: первый опыт клинического применения. Бюллетень сибирской медицины. 2021;20(1):23–30. DOI: 10.20538/1682-0363-2021-1-23-30.
24. Брагина О.Д., Чернов В.И., Зельчан Р.В., Медведева А.А., Фролова И.Г., Дудникова Е.А. и др. Оценка распространенности опухолевого процесса с применением радиофармпрепарата на основе меченных технецием-99m таргетных молекул у больной раком молочной железы с гиперэкспрессией Her2/neu (клиническое наблюдение). Сибирский онкологический журнал. 2021;20(5):170–178. DOI: 10.21294/1814-48612021-20-5-170-178.
25. Shilova O.N., Deyev S.M. DARPins: Promising scaffolds for theranostics. Acta Naturae. 2019;11(4):42–53. DOI: 10.32607/20758251-2019-11-4-42-53.
26. Vorobyeva A., Schulga A., Konovalova E., Güler R., Löfblom J., Sandström M. et al. Optimal composition and position of histidine-containing tags improves biodistribu tion of 99mTc-labeled DARPin G3. Scientific Reports. 2019;9(1):9405. DOI: 10.1038/s41598-019-45795-8.
27. Bragina O., Chernov V., Schulga A., Konovalova E., Garbukov E., Vorobyeva A. et. al. Phase I trial of 99mTc-(HE)3-G3, a DARPin-based probe for imaging of HER2 expression in breast cancer. Journal of Nuclear Medicine. 2021. DOI: 10.2967/jnumed.121.262542.
28. Брагина О.Д., Деев С.М., Чернов В.И., Толмачев В.М. Эволюция таргетной радионуклидной диагностики HER2-позитивного рака молочной железы. Acta Naturae. 2022;14(2):4–15.
Review
For citations:
Bragina O.D., Chernov V.I., Deyev S.M., Tolmachev V.M. Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins. Bulletin of Siberian Medicine. 2022;21(3):132-139. https://doi.org/10.20538/1682-0363-2022-3-132-139
Views:
487
Email this article 